RxDoctor Payments Data

Brenda Montecalvo

Vision Therapy · Dayton, OHNPI 1649320706

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,323 of the $1,727 with a category attached, or 76.6%. 7 manufacturers reported payments, led by Alcon at 48.1% of the total. Reporting peaked in 2023 at $948 and has fallen 67.7% since, to $306 in 2024.

$1,727in general payments, 2019–2025

Across 33 payments — averaging $52.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$830
  • Coopervision Inc.$342
  • Bausch & Lomb Americas Inc.$225
  • Johnson & Johnson Vision Care, Inc.$199
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$87
  • Optos, Inc.$29
  • plus $15 from 1 others

What the payments were for

  • Speaking & faculty fees$37522%
  • Food & beverage$1,32377%
  • Entertainment$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vision therapy providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$28,873
Medicare patients
153
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost37$308

Paid to pharmacies, not to this prescriber.

Other vision therapy in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →